Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
Related Articles
-
3M beats profit estimates on price hikes, cost cuts
3M said its dividend payout ratio is expected to be 40% of adjusted free cash flow, with a potential to increase over time following the spin off of its healthcare business. The company has benefited from steady price increases across categories, which have helped it offset inflation and slow demand in its electronics business. "We improved performance in our businesses through strong operational execution, completed the spin-off of Solventum, and finalized two major legal settlements,"...
-
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
-
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business.